Asia has become difficult to ignore in clinical development. Asia-Pacific is now the region where trial activity has grown most consistently over the past five years, and industry analysis puts China alone above 5,000 registered trials in 2025 — roughly double its 2020 figure. Growth of that kind attracts sponsors, but it also flatters the picture. A country can host a great many studies while individual hospitals remain slow to start up, thin on trained coordinators and unreliable on data quality.
:antCitation[]{citations=”13d98144-5e86-431f-90e9-0688ff81136d”}
For a hospital board or a medtech company planning its first pivotal study, the useful question is not how many trials a country runs. It is whether a specific site can deliver a specific protocol, on time, to a standard that will survive inspection. That question has measurable answers.
The regulatory baseline has moved
Three changes in the last two years have reset what “research-ready” means, and none of them is optional for institutions that want international work.
The first is Good Clinical Practice. The revised ICH guideline E6(R3) was adopted on 6 January 2025, and its overarching principles and Annex 1 came into effect in the European Union on 23 July 2025, with Annex 2 adopted in June 2026 and due to take effect on 15 January 2027. The revision is not cosmetic. It reframes quality as something designed into a trial rather than inspected after the fact, asks sponsors and investigators to identify what is genuinely critical to participant safety and result reliability, and sets clearer expectations for computerised systems used to capture and manage data. Annex 2 extends the framework to decentralised and pragmatic designs and to the use of real-world data — relevant to any hospital planning remote visits or registry-linked studies.
:antCitation[]{citations=”8db5f467-63bd-4024-be0d-234526b87581,9d3e1cb5-fa31-4833-a9bd-79cd6330c5c1″}
The second is ethics. The 2024 revision of the Declaration of Helsinki was adopted unanimously at the World Medical Association’s General Assembly in Helsinki in October 2024, following a 30-month process involving representatives from 19 countries. Its scope was widened so that researchers, teams and organisations — including industry — share responsibility for ethical conduct, and the language shifted from “subjects” to “participants”. Institutional responsibility is now explicit, which matters for hospitals that have historically treated ethics as the investigator’s problem.
:antCitation[]{citations=”02ede907-cd0d-4665-85c3-1b49ef8ab350,9f39e1e9-de93-4096-a2d5-bb4710c8870a”}
The third is system capability. WHO’s Guidance for best practices for clinical trials, issued in response to World Health Assembly resolution WHA75.8 (2022), addresses the design and conduct of trials and the strengthening of the wider trial ecosystem, with the aim of reducing research waste and sustaining trial capacity between emergencies. A regional consultation for the Western Pacific fed into that work, identifying equity in local research ecosystems, better data governance and systematic support for research integrity as priorities. WHO followed with an online course on good practices in clinical trials in May 2026, responding to member state requests for capacity building.
:antCitation[]{citations=”45498e5f-7ec2-454b-83c6-706af8d41461″}
Six measures that describe real site capability
Most site profiles circulated to sponsors describe inputs: bed numbers, specialist headcount, equipment lists. Sponsors make decisions on throughput and reliability. These six figures, tracked over the last eight to twelve studies, describe a site far better than any capability deck.
| Measure | What it tells a sponsor | Common failure pattern |
|---|---|---|
| Start-up cycle time — ethics submission to first participant enrolled | Whether governance, contracting and pharmacy set-up run in parallel or in series | Contract negotiation begins only after ethics approval, adding months |
| Enrolled participants per activated site per month, against the recruitment plan | Whether the referral pathway is real or theoretical | Feasibility estimates drawn from clinic volume rather than eligible, consenting patients |
| Screen failure rate | Quality of pre-screening and realism of eligibility assessment | High failure rates absorbing coordinator time and sponsor budget |
| Protocol deviation rate, and whether deviations cluster | Whether training and workload are adequate | Repeat deviations in the same visit window, signalling a process fault rather than isolated error |
| Median data query resolution time and the proportion open beyond 30 days | Data management discipline and coordinator capacity | Query backlogs that surface only at database lock |
| Retention and loss-to-follow-up rate | Participant burden, travel realities and the strength of the site relationship | Attrition concentrated after the most demanding visit |
Tracking these figures serves the institution as much as the sponsor. A site that cannot produce them has no basis for arguing that it deserves the next study.
Registration and regional design
Prospective registration is now a baseline expectation of journals, funders and many regulators. Several Asian registries sit inside the WHO registry network: the Chinese Clinical Trial Registry, the Clinical Research Information Service in the Republic of Korea, the Clinical Trials Registry – India, the Japan Registry of Clinical Trials and the Thai Clinical Trials Registry all meet the WHO primary registry criteria. Other markets in Southeast Asia operate national research registration systems that sit outside that network, so multi-country studies frequently register centrally while still satisfying local submission requirements. Confirming which route applies, before the first submission, avoids retrospective registration problems that are difficult to repair.
:antCitation[]{citations=”65ae3dea-7aae-42c2-9c6c-a7ed46298207″}
Regional design deserves the same early attention. ICH E17, adopted in November 2017, sets out general principles for planning and designing multi-regional clinical trials, including how regions are defined, how participants are allocated across them and how consistency of effect is examined. The consequences of ignoring it are not theoretical. In February 2022, a United States Food and Drug Administration advisory committee voted 14 to 1 that an additional trial should be required before a regulatory decision on a cancer therapy studied exclusively in China, citing the single-country design and a comparator that did not reflect standard practice in the United States. For sponsors in Asia, that precedent argues for designing regional breadth in from the start rather than retrofitting it after a submission stalls.
:antCitation[]{citations=”a0e4a30a-b168-4811-afab-e68d4af3bdca,1c21b4af-1f9b-41cf-8754-886e82909fa9″}
What a research milestone proves — and what it does not
Research programmes generate figures that organisations understandably want to publicise: sites activated, participants recruited, investigators trained, years of continuous operation. These are legitimate achievements. They are also frequently described in ways that imply something they cannot support.
| Type of claim | Example | What can support it | What cannot |
|---|---|---|---|
| Operational milestone | A defined number of participants enrolled across a stated network within a stated period | Source documents, registry entries, audited enrolment logs, independent verification | Any inference about treatment benefit |
| Capability claim | A site consistently activates studies within a stated timeframe | Cycle-time data across multiple completed studies, sponsor audit findings | A single fast start-up, or an accreditation certificate on its own |
| Clinical claim | A treatment improves outcomes for a defined population | Adequately powered, prospectively registered trials; systematic review; regulatory assessment | Enrolment volume, awards, market share, recognition of any kind |
The third row is where reputational damage usually originates. An impressive recruitment figure says something real about logistics, community trust and coordinator skill. It says nothing whatsoever about whether the investigational product works.
Documenting institutional achievement without overstating it
Asia’s healthcare organisations have limited vocabulary for operational excellence. Accreditation confirms that a facility meets defined standards. Awards reflect a judging panel’s opinion against criteria that vary in rigour. Neither is designed to document a single, quantified, one-off achievement — the largest programme of its kind in the region, a first documented institutional milestone, an unprecedented scale of participation.
That is the narrow space independent record recognition in Asia occupies. Platforms such as Asia Record assess a proposed achievement against submitted evidence of what was measured, how it was measured and the conditions under which it was achieved. For a hospital group, research network or medical technology company, the discipline of assembling that evidence is often more valuable than the recognition itself: it forces a defensible definition, a verifiable measurement and a clear boundary around what is being claimed. An organisation considering whether a documented milestone might qualify can review the eligibility and record application requirements before committing resources to it.
Two cautions apply. Record certification in Asia is not a regulatory approval, an accreditation or a substitute for either — a research site still needs its ethics approvals, its regulatory authorisations and its quality systems, and no recognition changes that. And recognition of scale must never be presented as evidence of clinical effectiveness. Becoming an Asia Record holder for a measurable programme milestone documents what an organisation did; it does not evaluate whether a therapy works. Organisations that keep those two statements clearly separated protect their credibility with the audience that matters most — regulators, sponsors and clinicians.
Before accepting a multiregional study: a short readiness check
- Can the site produce start-up cycle times, enrolment rates and query resolution figures from its last eight studies without reconstructing them?
- Has the feasibility estimate been validated against eligible patients in the clinic, not the total patient population?
- Do contracting, ethics submission and pharmacy set-up run in parallel, with named owners for each?
- Are coordinator caseloads counted in concurrent studies per person, and is that number defensible?
- Have GCP training records been updated to reflect the current version of E6, rather than the version in force when staff were first certified?
- Are the electronic systems in use documented as fit for their purpose, with access controls and audit trails a sponsor could inspect tomorrow?
- Does the ethics committee’s review calendar match the study’s planned timeline, including for protocol amendments?
- Is it clear who is accountable for prospective registration, and in which registry?
Mistakes that recur
- Selling capacity instead of throughput. Bed counts and specialist numbers do not predict enrolment; historical enrolment does.
- Treating GCP certification as a static asset. Guidance has changed; training records that predate it are a finding waiting to happen.
- Designing for one market and hoping for reciprocity. Regional breadth is far cheaper to plan than to add later.
- Publicising enrolment figures without a stated definition. A number with no denominator, period or verification method invites scepticism rather than credit.
- Letting marketing language drift from operational achievement to clinical benefit. This is the single most common way a legitimate milestone becomes a liability.
Asia’s share of global clinical research will keep rising. Which institutions benefit from that shift will depend less on national trial counts than on whether individual hospitals, networks and companies can demonstrate — with figures they already hold — that they are capable of delivering research that stands up to scrutiny.